[单倍型相合造血干细胞移植治疗青少年粒单核细胞白血病的临床研究]
[Clinical Study on Treatment of Juvenile Myelomonocytic Leukemia with Haploidentical-Hematopoietic Stem Cell Transplantation].
作者信息
Ding Li, Zhu Heng, Han Dong-Mei, Wang Zhi-Dong, Zheng Xiao-Li, Dong Lei, Yan Hong-Min, Liu Jing, Zhu Ling, Xue Mei, Guo Zi-Kuan, Wang Heng-Xiang
机构信息
Department of Hematology, Air Force General Hospital of Chinese PLA, Beijing 100142, China.
Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850, China.
出版信息
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Oct;25(5):1524-1527. doi: 10.7534/j.issn.1009-2137.2017.05.043.
OBJECTIVE
To analyze the therapeutic efficacy of haploidentical-hematopoietic stem cell transplantation (hi-HSCT) for patients with juvenile myelomonocytic leukemia (JMML).
METHODS
The engraftment of hematopoietic stem cells, incidence of graft versus host disease (GVHD), infection, relapse, and survival of 6 JMML patients received hi-HSCT were retrospectively analyzed.
RESULTS
Six (6 males) JMML patients received hi-HSCT from haplo-HLA-matched related donors. The results showed that the hematopoictic stem cells in all 6 patients were grafted successfully. Two cases of JMML died of pulmenary infections, other 4 cases survive without disease. Acute GVHD occurred in 3 patients and chronic GVHD occurred in 1 patients. The overall survival, disease free survival and relapse rates were 66.7%, 66.7%, 0%, respectively.
CONCLUSION
The hi-HSCT is an effective method for treatment of patients with JMML, but there also is a serial problems to be resolved.
目的
分析单倍体相合造血干细胞移植（hi-HSCT）治疗青少年粒单核细胞白血病（JMML）患者的疗效。
方法
回顾性分析6例接受hi-HSCT的JMML患者的造血干细胞植入情况、移植物抗宿主病（GVHD）发生率、感染、复发及生存情况。
结果
6例（均为男性）JMML患者接受了来自单倍体HLA匹配的相关供者的hi-HSCT。结果显示，6例患者的造血干细胞均成功植入。2例JMML患者死于肺部感染，其他4例无病存活。3例发生急性GVHD，1例发生慢性GVHD。总生存率、无病生存率和复发率分别为66.7%、66.7%、0%。
结论
hi-HSCT是治疗JMML患者的有效方法，但也存在一系列问题有待解决。
Zotero 插件